Christopher Richard Anzalone - 07 Jan 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role: Chief Executive Officer, Director
Signature: /s/ Christopher Anzalone
Issuer symbol: ARWR
Transactions as of: 07 Jan 2022
Net transactions value: +$61,273
Form type: 4
Filing time: 07 Jan 2022, 20:39:27 UTC
Previous filing: 04 Jan 2022
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARWR	Common Stock	Options Exercise	$61,273	+11,806	+0.29%	$5.19^*	4,057,634	07 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARWR	Stock Option (right to buy Common Stock)	Options Exercise	$0	-11,806	-1.5%	$0.000000	761,421	07 Jan 2022	Common Stock	11,806	$5.19	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.
F2	Represents first vesting date. Option vested over four years from date of grant.
F3	Represents total stock options beneficially owned at various strike prices.